Whalesbook
Shaily Plastics mein achanak yeh tezi kyun?
Is stock mein 22 April se 28 April 2026 ke beech lagbhag 30% ka jump dekha gaya, jisne ise ₹2,500 ke paas pahuncha diya. Iska sabse bada reason hai company ka healthcare sector mein badhta focus, khaas kar GLP-1 jaise high-demand drugs ki delivery devices banane mein. Institutional investors bhi enter kar rahe hain, jaise Smallcap World Fund ne apna stake badhaya hai. Yeh sab dekh kar lagta hai ki company ki precision manufacturing capabilities par bharosa badh raha hai.
Healthcare revenue mein toofani speed!
Q3 FY26 mein Shaily ka healthcare revenue 139% saal-dar-saal badhkar ₹104.3 crore ho gaya, jabki consumer segment 13% gir gaya. Isse overall revenue 27% badhkar ₹250.5 crore aur EBITDA 43% badhkar ₹66.4 crore ho gaya, jisme margins 26.5% rahe. Yeh sab chal raha hai kyunki diabetes aur obesity ke liye GLP-1 drugs ki global demand badh rahi hai, jo 2030 tak $100 billion se zyada ho sakti hai. Shaily pen injectors aur auto-injectors jaise critical devices banati hai. Pichhle ek saal mein stock ₹1,460 se ₹2,799.20 ke beech raha hai.
Valuation aur Performance ka funda
Shaily ka valuation lagbhag 80x P/E ke aas-paas hai, matlab market ko steady high growth ki umeed hai. Yeh apne peers jaise Supreme Industries (~55x P/E) ya Astral Ltd (~85x P/E) se zyada hai. Company ka ROCE 38.4% aur ROE 29.1% (December 2025 tak) healthcare business ke karan kaafi sudhre hain. Haalanki, pichhle teen saal mein revenue growth 9.26% thi, jo profit growth 26.37% se kam hai. Analyst mostly positive hain aur unka average 12-month target price ₹3,526 ke aas-paas hai.
Lekin ek badi chinta bhi hai!
Par bhai, itni khushi mein ek bada risk bhi chhipa hai. Company ka business ab healthcare, khaas kar GLP-1 devices par bahut zyada depend karta hai. Agar is segment mein koi bhi problem hui, toh seedha Shaily ki revenue par asar padega. Iske alawa, Abu Dhabi mein ₹300-350 crore ka naya plant lagane ki planning hai jo Q4 FY28 tak start ho sakta hai. Yahan 50-60% capacity already committed hai, par agar yeh expansion mein deri hui ya zyada paisa lag gaya, toh company ki finances par pressure aa sakta hai. Current valuation 80x earnings ke aas-paas hai, jo tabhi justify hoga jab growth projections sach hon aur facility smoothly chal pade, warna stock mein badi girawat ho sakti hai. Company ka debt level abhi 0.3x net debt to equity hai jo theek hai, par naye project se yeh badhega.
Aage ka plan kya hai?
Shaily ka focus GLP-1 opportunity ko pakadne aur global manufacturing ko badhane par hai. Pen injector capacity ko 80 million se 150 million units annually tak badhaane ka plan hai Q4 FY28 tak. Naye contracts bhi mil rahe hain, jaise pen injectors ke liye ₹423 crore ka deal. Ab sab kuch is par depend karta hai ki company apni manufacturing strength aur badhi hui capacity ko consistent, profitable growth mein kaise badalti hai jo uske premium valuation ko sahi thehraye.